Pfizer to discontinue twice-daily weight loss pill due to high rates of adverse side effects
Pfizer said it still plans to release phase two trial data on a once-a-day version of its weight loss drug, known as danuglipron, in the first half of 2024.
Similar Posts
FDA okays US clinical testing for Immix drug NXC-201
Post Content Post Views: 129
US thwarted plot to kill Sikh separatist in America
Post Content Post Views: 119
Pfizer’s twice-daily weight loss pill joins a long list of obesity drug flops
Before successful weight loss treatments such as Wegovy and Ozempic, the pharmaceutical path to treating obesity was strewn with failures dating back decades. Post Views: 115
California governor calls for statewide generative AI training
Post Content Post Views: 127
Tesla’s union problems in Sweden include trash piling up and no mail service
Post Content Post Views: 116
Metro renews buyback program to repurchase about 7M shares
Post Content Post Views: 131